The identification of biomarkers of cancer risk, treatment response and progression, including genetic polymorphisms, epigenetic alterations, infectious agents and aberrant levels of proteins, hormones and nutrients has become an increasingly important aim of investigators with peer-reviewed funding at Fox Chase Cancer Center (FCCC), The Cancer Prevention Biomarker and Genotyping Facility (CPBGF) was established in 2001 as a developing Core Facility and provides a centralized resource for cost-effective genotyping services and biomarker assays to support research-based human population and mouse studies. Genotyping services include the analysis of polymorphic variation and mutations within normal or tumor DMA utilizing state-of-the-art instrumentation and technology. Assessment of host genotype and tissue-specific alterations in DNA sequence aids in identifying predictive genetic biomarkers of cancer risk and treatment response as well as surrogate endpoints for chemoprevention. Mouse genotyping services also aid researchers in the breeding and maintenance of their transgenic and knockout strains. In addition to genotyping, the Facility performs assays for the analysis of potential environmental and behavioral biomarkers of cancer risk (i.e., tobacco metabolites and bisphenol) as well as dietary factors, which can be measured in tissues and biofluids. This new Core Facility is directed by Cynthia Spittle, Ph.D. Since its inception in 2001, the Facility has provided services for a total of 18 FCCC investigators in six Research Programs in all three Divisions. In 2003, >94% of usage was from investigators with peer-reviewed funding. There has been >200% increase in the number of genotyping assays performed during the first three years of operation. The services provided by the CPBGF benefit clinicians, epidemiologists and behavioral scientists with interests in cancer prevention and pharmacogenetics research and basic scientists who utilize mouse models in their work. The demand for genotyping and biomarker analyses is expected to continue to grow over the next five years. The CPBGF offers distinctive and non-duplicative services that are a vital addition to the support offered to investigators with peer-reviewed funding. During the next five years, the CPBGF will expand its services, staffing, and infrastructure in a cost-effective manner in order to best meet the needs of investigators with peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-44
Application #
7310521
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
44
Fiscal Year
2006
Total Cost
$56,773
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Shaikh, Talha; Wang, Lora S; Egleston, Brian et al. (2018) Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol 41:59-64
Campbell, Kerry S; Cohen, Adam D; Pazina, Tatiana (2018) Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front Immunol 9:2551
Blackman, Elizabeth; Ashing, Kimlin; Gibbs, Denise et al. (2018) The Cancer Prevention Project of Philadelphia: preliminary findings examining diversity among the African diaspora. Ethn Health :1-17
Fatkhullina, Aliia R; Peshkova, Iuliia O; Dzutsev, Amiran et al. (2018) An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. Immunity 49:943-957.e9
Gupta, Sapna; Kelow, Simon; Wang, Liqun et al. (2018) Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine ?-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem 293:13921-13931
Sementino, Eleonora; Menges, Craig W; Kadariya, Yuwaraj et al. (2018) Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952-8961
Araiza-Olivera, Daniela; Chernoff, Jonathan (2018) Hras helps hippo heterodimerize to evade tumor suppression. Small GTPases 9:327-331
Peng, Hongzhuang; Prokop, Jeremy; Karar, Jayashree et al. (2018) Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. Cancer Res 78:1200-1213
Reese, Jennifer Barsky; Smith, Katherine Clegg; Handorf, Elizabeth et al. (2018) A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. J Psychosoc Oncol :1-22
Shaikh, Talha; Handorf, Elizabeth A; Meyer, Joshua E et al. (2018) Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol 4:e173580

Showing the most recent 10 out of 1280 publications